Published online before print October 6, 2005, doi: 10.1161/01.RES.0000189262.92896.0b
© 2005 American Heart Association, Inc.
Cellular Biology |
Intrasarcoplasmic Amyloidosis Impairs Proteolytic Function of Proteasomes in Cardiomyocytes by Compromising Substrate Uptake
From the Cardiovascular Research Institute (Q.C., J.-B.L., K.M.H., H.Z., A.R.K.K., J.L., F.L., A.M.G., X.W.), South Dakota Health Research Foundation, University of South Dakota School of Medicine and Sioux Valley Hospitals and Health System, Sioux Falls; National Eye Institute (E.F.W.), National Institutes of Health, Bethesda, Md; Department of Pathophysiology (J.-B. L), Guangzhou Medical College, Guangzhou, Guangdong, China; and Department of Laboratory Medicine (F. L.) and Division of Basic Biomedical Sciences (Q.C., J.-B.L., K.M.H., H.Z., A.R.K.K., J.L., X.W.), University of South Dakota School of Medicine, Sioux Falls.
Correspondence to Xuejun Wang, MD, PhD, Cardiovascular Research Institute, University of South Dakota School of Medicine, 1100 E 21st St, Ste 700, Sioux Falls, SD 57105. E-mail xwang{at}usd.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The presence of increased ubiquitinated proteins and amyloid oligomers in failing human hearts strikingly resembles the characteristic pathology in the brain of many neurodegenerative diseases. The ubiquitin–proteasome system (UPS) is responsible for degradation of most cellular proteins and plays essential roles in virtually all cellular processes. UPS impairment by aberrant protein aggregation was previously shown in cell culture but remains to be demonstrated in intact animals. Mechanisms underlying the impairment are poorly understood. We report here that UPS proteolytic function is severely impaired in the heart of a mouse model of intrasarcoplasmic amyloidosis caused by cardiac-restricted expression of a human desmin–related myopathy-linked missense mutation of
B-crystallin (CryABR120G). The UPS impairment was detected before cardiac hypertrophy, and failure became discernible, suggesting that defective protein turnover likely contributes to cardiac remodeling and failure in this model. Further analyses reveal that the impairment is likely attributable to insufficient delivery of substrate proteins into the 20S proteasomes, and depletion of key components of the 19S subcomplex may be responsible. The derangement is likely caused by aberrant protein aggregation rather than loss of function of the CryAB gene because UPS malfunction was not evident in CryAB-null hearts and inhibition of aberrant protein aggregation by Congo red or a heat shock protein significantly attenuated CryABR120G-induced UPS malfunction in cultured cardiomyocytes. Because of the central role of the UPS in cell regulation and the high intrasarcoplasmic amyloidosis prevalence in failing human hearts, our data suggest a novel pathogenic process in cardiac disorders with abnormal protein aggregation.
Key Words: proteasome • ubiquitin • protein aggregation • B-crystallin • desmin-related cardiomyopathy • amyloidosis • transgenic mice
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Most cellular proteins are degraded through the ubiquitin–proteasome system (UPS). UPS-mediated proteolysis includes 2 major steps: attachment of a chain of ubiquitin to the target protein molecule through a process known as ubiquitination and degradation of the ubiquitinated proteins by the 26S proteasome. The latter consists of a barrel-shaped 20S core and the 19S cap on 1 or both ends of the 20S. The actual proteolytic activity resides in the interior of the 20S, whereas the 19S plays a critical role in channeling ubiquitinated protein molecules into the 20S.1 Ubiquitinated proteins accumulate in the cell when the proteasome is inhibited.1 Aberrant protein aggregation is a common process in many neural degenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s diseases.2,3 Remaining to be demonstrated in intact animals, this process was shown in cell culture to impair UPS-mediated proteolysis.4 Therefore, UPS malfunction is considered an important pathogenic mechanism in neurodegeneration.5
Recent studies revealed that abnormal protein aggregation, intrasarcoplasmic amyloidosis (IA), and accumulation of ubiquitinated proteins are also very common phenomena in human hearts with idiopathic or ischemic cardiomyopathies.6–9 These observations, especially the discovery that very abundant amyloid-positive substance is strikingly associated with myofibrils in most human hearts with dilated or hypertrophic cardiomyopathies, suggest IA as a potential major pathogenic process in congestive heart failure (CHF).8 Hence, elucidation of the effect of IA on UPS-mediated proteolysis may provide significant insight into the molecular pathogenesis of CHF.
A missense mutation (R120G) in the B-crystallin (CryAB) gene encoding a molecular chaperone highly expressed in the heart has been shown to cause aberrant protein aggregation in the heart and result in desmin-related cardiomyopathies (DRC) in humans and transgenic (Tg) mice.10,11 Mice carrying 3 copies of a Tg consisting of the mouse -myosin heavy chain promoter and the CryABR120G cDNA show no apparent cardiac abnormality at 1 month but develop concentric cardiac hypertrophy with diastolic malfunction at 3 months and die of CHF between 5 and 7 months.11 It was recently demonstrated that CryABR120G mice were a model of cardiac IA, resembling a prominent feature in failing human hearts.8 Therefore, CryABR120G mice are used as an animal model to study the pathogenesis of aberrant protein aggregation and IA in the present study. We hypothesized that aberrant protein aggregation induced by CryABR120G impairs UPS proteolytic function in the heart, representing a nodal pathogenic process in cardiac remodeling and failure in DRC. We present here several lines of evidence that clearly support this hypothesis. We have demonstrated in intact animals that expression of a misfolded and aggregation-prone cytosolic protein impairs the proteolytic function of the UPS in the heart before other cardiac pathology becomes discernible. The defect appears to reside in the delivery of ubiquitinated protein molecules into the proteolytic cavity of the 20S proteasomes, and depletion of key components of 19S proteasomes may be responsible. Using cultured cardiomyocytes, we have further proven that aberrant protein aggregation is an essential process for CryABR120G to induce proteasomal malfunction. Because aberrant protein aggregation and accumulation of ubiquitinated proteins, both indicative of malfunction in protein quality control, have been frequently observed in failing human hearts, protein aggregation-induced UPS malfunction likely represents a potentially important pathogenic process in not only DRC but also other cardiac disorders with protein misfolding.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
An expanded Materials and Methods section is available in the online data supplement at http://circres.ahajournals.org.
Tg Mice
FVB/N Tg mice with cardiac-specific overexpression of CryABR120G or wild-type (WT)-CryAB have been described.8,11 Generation of CryAB-null mice has been reported previously.12 FVB/N Tg mice ubiquitously expressing a reporter substrate (GFPdgn) of the UPS are described elsewhere.13 GFPdgn is created by fusion of degron CL-1 to the carboxyl terminus of the conventional green fluorescent protein (GFP). Previous studies have proven that this modification renders GFP a specific substrate for the UPS and that resultant GFPdgn can serve as a dynamic indicator for the proteolytic function of the UPS in cardiomyocytes.4,14 All animals used in this study were produced by the Laboratory Animal Facility of the University of South Dakota. Institutional guidelines for the care and use of the animals were followed.
In Vitro GFPdgn Degradation Assay
To assess the proteolytic function of the entire UPS, GFPdgn was purified from the skeletal muscle of GFPdgn mice by immunoaffinity chromatography (Pierce). Equal amounts of GFPdgn protein were incubated with 10 µg of soluble protein from ventricular myocardium. The reactions were performed in 25 mmol/L Tris-HCl buffer containing ATP (2 mmol/L) and MgCl2 (2 mmol/L) for 30 minutes in the presence or absence of MG-132 (10 µmol/L). The reactions were stopped by adding 3x SDS-PAGE sampling buffer and immediately followed by boiling for 5 minutes. The end product was then fractionated by 12% SDS-PAGE and immunoprobed for GFPdgn.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Ubiquitinated Proteins Were Progressively Increased in CryABR120G Mouse Hearts
Because cardiac expression of CryABR120G not only recapitulates manifestations of human DRC but also displays IA that is frequently observed in non-DRC failing human hearts,8,11 CryABR120G Tg mice serve as a valuable model to dissect mechanisms underlying CHF. To explore the pathogenesis of CryABR120G, we found that ubiquitinated proteins in both the soluble fraction and total protein extracts from the heart progressively increased in CryABR120G Tg but not WT-CryAB Tg mice at 1 month and 3 months, whereas free ubiquitin remained unchanged compared with Ntg littermates (Figure 1A through 1D). Ubiquitinated proteins are normally degraded efficiently by the 26S proteasomes.1 An increase in ubiquitinated proteins indicates either proteasomal malfunction or enhanced ubiquitination. Because the overexpression of CryABR120G at the transcript level is much less than overexpression of WT-CryAB in these Tg mice,11 increased ubiquitination resulting from CryAB protein overexpression could not account for the significant difference in ubiquitinated protein levels between CryABR120G and WT-CryAB Tg hearts. Therefore, these findings suggest that the 26S proteasome is likely malfunctioning in CryABR120G expressing hearts.
|
UPS Ability to Degrade a Surrogate Substrate Was Progressively Diminished in CryABR120G Mouse Hearts, Whereas Proteasomal Peptidase Activities Were Not Reduced
We have recently established and validated a Tg mouse model in which a reporter substrate (GFPdgn) of the UPS is ubiquitously and constitutively expressed in all the major organs.13 Changes in GFPdgn protein levels inversely reflect the proteolytic function of the UPS. To probe UPS proteolytic function in CryABR120G mouse hearts, we crossbred CryABR120G or WT-CryAB Tg mice with GFPdgn mice. As observed in hearts treated with specific proteasome inhibitors,13 GFPdgn protein was dramatically increased in CryABR120G/GFPdgn double-Tg hearts at both 1 month and 3 months, compared with GFPdgn single-Tg hearts of littermates. GFPdgn protein was not increased in WT-CryAB/GFPdgn double-Tg hearts (Figure 2A through 2C). Consistently, direct fluorescence confocal microscopy of myocardium showed clearly increased green fluorescence intensities in the cardiomyocytes of CryABR120G/GFPdgn double-Tg hearts (Figure 3). The increase in GFPdgn protein in CryABR120G/GFPdgn double-Tg hearts was greater at 3 months than at 1 month (Figures 2C and 3 
). This increase in GFPdgn protein is attributable to decreased degradation rather than increased synthesis, because the steady-state GFPdgn transcript level was not increased in CryABR120G/GFPdgn double-Tg hearts compared with GFPdgn single-Tg hearts (Figure 2D and 2E). Furthermore, the ability of crude protein extracts from CryABR120G hearts to degrade in vitro GFPdgn protein immunoprecipitated from the skeletal muscle of GFPdgn mice was significantly compromised compared with Ntg littermates or WT-CryAB Tg controls (Figure 2F). These tests prove that cardiac UPS proteolytic function is significantly impaired by expression of CryABR120G.
|
|
The free ubiquitin levels were not altered. Moreover, ubiquitinated proteins were significantly increased in CryABR120G hearts (Figure 1), suggesting that the primary cause of UPS malfunction in these hearts is not at ubiquitin conjugation but rather in the 26S proteasome. The latter is composed of the 19S and the 20S subcomplexes. The 19S is believed to recognize ubiquitinated protein molecules, de-ubiquitinate and unfold them, and channel the unfolded protein to the 20S, where actual proteases reside. The 20S proteasome is a hollow cylindrical protein complex composed of 2 central antiparallel ß rings flanked by 2 identical rings. Each or ß ring consists of 7 protein molecules (1 to 7 and ß1 to ß7). The unfolded protein is believed to be degraded in the cavity of the 20S by 3 major peptidase activities: chymotrypsin-like, trypsin-like, and caspase-like (also known as peptidylglutamyl-peptide hydrolase) activities, which reside in the ß5, ß2, and ß1 subunits, respectively.1 We measured these peptidase activities using synthetic fluorogenic substrates and crude protein extracts from the heart. WT-CryAB Tg mice do not show any abnormal phenotype, and the UPS proteolytic function in their hearts does not differ from Ntg littermates (Figures 1 through 3
). Therefore, for brevity, WT-CryAB Tg mice were not included in studies described in Figures 4 and 5 . Compared with Ntg littermates, all 3 forms of peptidase activities were, surprisingly, not decreased in CryABR120G hearts at 1, 3, or 6 months. On the contrary, trypsin-like activities were significantly increased at all of the 3 time points, especially at 3 and 6 months, and the chymotrypsin-like and the caspase-like activities were also significantly increased at 6 months when CHF becomes overt (Figure 4). These findings suggest that the impairment of proteasomal proteolytic function in CryABR120G hearts is attributable to a defect in the uptake of ubiquitinated proteins into 20S proteasomes rather than altered peptide cleavage activities of the 20S. It is generally accepted that the 19S proteasome and its interaction with the rings of the 20S regulate and mediate the entry of targeted protein molecules into the 20S.15 Consistently, the protein abundance of the 20S components (6, ß2, ß5, and the precursor of ß5) was significantly increased, whereas key components (Rpt3 and Rpt5) of the 19S evidently decreased in CryABR120G hearts at 3 and 6 months (Figure 5).
|
|
Aberrant Protein Aggregation Plays an Essential Role in UPS Impairment by CryABR120G
CryABR120G is misfolded and aggregation prone. Its presence dominantly inhibits the chaperone function of normal CryAB.16,17 To ascertain whether UPS impairment by CryABR120G is caused by loss of function of CryAB, we examined UPS functional status in CryAB-null mouse hearts at &2 to 3 months, when no discernible phenotype is evident. Compared with age-matched wild-type mice of the same genetic background, neither the abundance of ubiquitinated proteins nor proteasomal peptidase activities were significantly altered in the CryAB-null hearts (data shown in the online data supplement). This suggests that UPS malfunction observed in CryABR120G expressing hearts is not caused by loss of function of the CryAB gene. Because CryAB can oligomerize with other small heat shock proteins (Hsp) and may function in heterooligomers,17 the results from CryAB-null mice do not rule out a possible contribution of the dominant negative activity of CryABR120G to the UPS malfunction.
In cultured HEK cells, aberrant protein aggregation of mutant huntingtin and cystic fibrosis membrane conductor protein was shown to be sufficient to impair the UPS.4 Adenovirus-mediated overexpression of truncated cardiac myosin-binding protein C mutants were recently shown to impair the UPS in cultured NRVMs and form abnormal aggregates, but a causal relationship between aberrant protein aggregation and UPS impairment was not tested.18 We have further addressed these critical issues in a well-established NRVM culture system. CryABR120G, WT-CryAB, and a UPS function reporter (GFPu or GFPu) similar to GFPdgn were introduced into cultured NRVMs via adenovirus infection. We reported that changes in GFPu protein levels in cultured NRVMs inversely reflect the proteolytic function of the UPS.14 As observed in Tg mouse hearts, expression of CryABR120G but not WT-CryAB caused significant increases of GFPu protein in cultured NRVMs in a dose-dependent manner (Figure 6A). The increase in GFPu protein levels marks a decrease in UPS proteolytic function because the synthesis of GFPu, as demonstrated by steady-state GFPu transcript levels, was not increased by coexpression of CryABR120G compared with coexpression of either WT-CryAB or ß-galactosidase (Figure 6B). These findings demonstrate that modest overexpression of CryABR120G, but not WT-CryAB, is sufficient to impair the UPS in cultured cardiomyocytes. Similar to what was observed in the heart, the abundance of free ubiquitin was not affected; however, the ubiquitinated proteins were significantly increased by CryABR120G but not WT-CryAB overexpression in cultured NRVMs (Figure 6C and 6D). These findings indicate that changes in ubiquitin conjugation do not likely contribute to the UPS proteolytic malfunction in CryABR120G-expressing cells. This is consistent with in vivo findings and implicates that the primary defect is in the proteasome.
|
The major pathological change in CryABR120G-expressing human and mouse hearts and in CryABR120G-expressing NRVMs is aberrant protein aggregation. CryAB-positive abnormal protein aggregates were observed in CryABR120G but not in WT-CryAB Tg hearts.11 In addition to relatively large and microscopically visible aggregates, SDS-soluble high molecular–weight CryAB oligomers, which are unable to pass through the nitrocellulose membrane with a pore size of 0.25 µm, were significantly increased in the CryABR120G hearts (Figure 7A, a) and CryABR120G-expressing NRVMs (Figure 7B). It has been well documented that molecular chaperones, such as Hsp and certain pharmacological agents (eg, Congo red), can bind misfolded proteins and effectively prevent them from aggregating, thereby assisting protein quality control in the cell.19–22 To test the necessity of abnormal protein aggregation in UPS impairment by CryABR120G, we determined the effect of reduction of protein aggregation by Congo red treatment or by overexpressing inducible Hsp70 in cultured NRVMs. Interestingly, as shown by the nitrocellulose filter-trapping assay, the prevalence of CryAB oligomers in the myocardial homogenate from CryABR120G hearts was dramatically reduced by in vitro treatment of Congo red (Sigma) in a dose-dependent manner (Figure 7A, b). Consistent with a previous report,8 the treatment of Congo red on NRVMs in primary culture significantly reduced the formation of both the microscopically visible protein aggregates (Figure 7D) and the soluble CryAB oligomers induced by expression of CryABR120G (Figure 7B and 7C). Importantly, this inhibition of aberrant protein aggregation by Congo red led to a significant attenuation of UPS malfunction, as evidenced by a significantly decreased GFPu accumulation (Figure 7B through 7D). Similar reduction in both CryAB oligomers and GFPu accumulation was also observed with coexpression of inducible Hsp70 (data not shown). These findings prove that aberrant protein aggregation plays an essential role in CryABR120G induced proteasomal malfunction.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
UPS-mediated proteolysis degrades abnormal proteins such as misfolded, oxidized, and mutant proteins, thereby serving as a critical quality control in the cell. The UPS also degrades normal proteins that are no longer needed. This regulatory degradation ensures timely removal of normal proteins, including signaling proteins and transcription regulators such as mitotic cyclins, CDK inhibitors, I
B, ß-catenin, and calcineurin when their jobs are done.1,23 Therefore, the UPS plays critical roles in virtually all important cellular processes, such as cell-cycle control, transcription regulation, signal transduction, and cell survival and homeostasis. Until very recently, the elucidation of the involvement of UPS dysfunction in pathogenesis of disease has been hindered by a lack of reliable methods to measure dynamic changes of UPS function in vivo. Recently established UPS functional reporter Tg mouse models make it possible to monitor in vivo dynamic changes in the proteolytic function of the entire UPS.24 Taking advantage of 1 such mouse model that we have recently created and validated,13 we have collected in the present study definitive in vivo evidence that modest cardiac overexpression of a human DRC-linked mutant CryAB impairs the proteolytic function of the UPS in the heart. This impairment occurred before cardiac hypertrophy, and malfunction became discernible. Cardiac remodeling and malfunction progressed as UPS function in the heart deteriorated progressively, suggesting that UPS malfunction likely participates in the pathogenesis of the mutant CryAB. Further analyses reveal that the UPS malfunction is mainly attributable to a defect in the delivery of ubiquitinated proteins into the proteolytic chamber of the 20S proteasome, and the depletion of key components of the 19S proteasome may be responsible. Because of accumulation of ubiquitinated proteins and alteration of proteasomal peptidase activities were not evident in CryAB-null mice, proteasomal malfunction in CryABR120G Tg hearts is unlikely caused by loss of function of the CryAB gene. Our findings from experiments with cultured NRVMs further suggest that aberrant protein aggregation is a major underlying mechanism by which misfolded CryAB causes proteasomal malfunction.
Tg Expression of CryABR120G Impairs the Delivery of Ubiquitinated Proteins Into 20S Proteasomes
By crossbreeding UPS functional reporter (GFPdgn) mice with CryABR120G Tg mice, we are able to prove that proteolytic function of the UPS is severely impaired in CryABR120G Tg hearts (Figures 1 through 3 ). However, conventional proteasomal peptidase activity assays failed to detect the impairment. On the contrary, all of the 3 peptidase activities showed significant increases in the CryABR120G heart at the CHF stage (Figure 4). These peptidase assays use synthetic fluorogenic substrates, which are small peptides and can easily diffuse into the proteolytic chamber of the 20S proteasome; therefore, they only measure the function of the 20S proteasomes.25 In the CryABR120G heart, ubiquitin conjugation does not appear to be a problem because ubiquitinated proteins are progressively increased (Figure 1A through 1D). The function of 20S proteasomes is unlikely to be the primary cause of observed proteasomal malfunction because conventional in vitro assays showed that their peptidase activities are not reduced at all but rather significantly increased at the CHF stage (Figure 4). These analyses suggest that the primary defect likely resides at the transport of ubiquitinated proteins to the 26S proteasome and the entry of ubiquitinated proteins into the 20S proteasome. The process by which target proteins are delivered into the proteolytic core of the 20S proteasome is incompletely understood. Although other proteins, such as the CDC48 protein complex, may be involved,26 it is generally believed that 19S proteasomes play a primary role in this process.1,15 Therefore, we assessed the abundance of key components of the 19S and the 20S proteasomes and discovered that Rpt3 and Rpt5 of the 19S were significantly decreased, whereas all of the examined subunits of the 20S were markedly increased in CryABR120G hearts at 3 and 6 months, when overt cardiac hypertrophy and malfunction were evident (Figure 5). It was reported that inhibition of proteasome activity in cultured mammalian cells induces concerted expression of proteasome genes including components of the 19S and the 20S and de novo formation of the 26S proteasome.27 This is considered a compensatory response to acquired proteasome malfunction. Hence, in CryABR120G hearts, which clearly show proteasome malfunction, the upregulation of 20S proteasome components is likely a compensatory response, whereas the depletion of 19S proteasome components is probably a cause for the deficiency in the delivery of ubiquitinated proteins into the 20S.
It is also worthwhile to note that discoveries presented here also illustrate that it can be very misleading to use proteasomal peptidase activity assays alone to evaluate the proteolytic function of the UPS or the proteasome.
UPS Impairment by Aberrant Protein Aggregation Is Potentially a Novel Pathogenic Process for Cardiac Remodeling and Failure
This postulate remains to be further tested, but it is consistent with multiple lines of direct and indirect evidence. First, aberrant protein aggregation is not just a feature for DRC but is rather a common phenomenon in human CHF. It was recently discovered that IA (a form of aberrant protein aggregation) from unknown proteins was frequently present in the cardiomyocytes of failing human hearts with either hypertrophic or dilated cardiomyopathies.8 Aberrant protein aggregation was also observed in ischemic cardiomyopathy and CHF resulting from dilated cardiomyopathy.6 Second, proteasomal malfunction has been implicated in failing human hearts. Immunohistologic studies of failing human hearts revealed that increased ubiquitin conjugates were colocalized with autophagic cell death, an important form of cell death in the failing heart.7 It was also reported that ubiquitinated protein levels were significantly increased in the heart with either dilated or ischemic cardiomyopathies,9 suggesting that proteasomal function is likely impaired in failing human hearts. Third, studies with cell culture have previously shown impairment of the UPS by aberrant protein aggregation.4,18 The present study proves that UPS proteolytic function is severely impaired by expression of an aggregation-prone protein in the heart of intact mice. Our additional tests with cultured NRVMs demonstrate that aberrant protein aggregation is not only sufficient but also essential for a mutant CryAB to impair UPS function. Although it has not been tested whether UPS malfunction causes or potentiates cardiac hypertrophy and/or failure, it has been reported that several signaling proteins, such as ß-catenin and calcineurin,1,23 which mediate cardiac growth, including pathological hypertrophy, are degraded by the UPS. Indeed, we found that cytosolic ß-catenin was significantly increased in CryABR120G Tg hearts at the CHF stage (supplemental Figure I). Activated calcineurin was previously found to be markedly increased in failing human hearts.28 It will be very important to determine whether the increase in these signaling proteins in CHF is attributable to a decrease in their degradation. Finally, proteasome inhibition leads to apoptosis, a major form of cell death that is considered an important mechanism underlying CHF.29 Cells, at least proliferating cells, defective in the UPS most often arrest near the G2/M boundary of the cell cycle and undergo apoptosis.30 We have previously observed that proteasomal inhibition by MG-132 increased cell death in cultured NRVMs.14 It has not been reported but should be extremely important to ascertain whether proteasome malfunction affects cardiomyocyte survival in vivo.
Sarcomeres are the most fundamental function units of cardiac contractility. Normal turnover of most sarcomeric proteins depends on the UPS.31,32 Failure to replace aged or damaged sarcomeric proteins would conceivably afflict the behavior and performance of myofibrils. Furthermore, the endoplasmic reticulum (ER) plays critical roles in the quality control of membrane proteins and proteins for secretion. The ER accomplishes this important task in partnership with the UPS. In fact, the proteasome is believed to be responsible for the degradation of all abnormal cellular proteins, thereby executing quality control in the cell.1 Prolonged ER stress has been reported as a mechanism underlying heart failure.33 It would not be surprising if UPS malfunction played an even greater role than prolonged ER stress in cardiac remodeling and failure.
It should be pointed out that the UPS is the major, but by no means the only, proteolytic pathway responsible for protein turnover in cardiomyocytes.32 Other pathways, such as the calpain proteolytic pathway and the lysosomal, autophagic pathway, also exist and likely play a role in cardiomyocytes.34,35 It is unknown but should be very interesting to investigate whether these other pathways compensate for UPS proteolytic deficiency.
|
Acknowledgments |
|---|
This work was supported by NIH grants HL72166 (to X.W.) and P20 RR-17662 (to A.M.G., X.W., and F.L.) and American Heart Association Scientist Development Grant 235099N (to X.W.). A.R.K. is supported by a Predoctoral Fellowship Grant (0510069Z) from the American Heart Association. We thank Dr Jeffrey Robbins for generously providing the WT-CryAB and CryABR120G Tg mouse models. We also thank the Cell Culture Core in the Cardiovascular Research Institute of the University of South Dakota for technical assistance in NRVM culture.
|
Footnotes |
|---|
*Both authors contributed equally to this work.
Original received June 27, 2005; revision received September 20, 2005; accepted September 27, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002; 82: 373–428.
2. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med. 2004; 10 (suppl): S2–S9.[CrossRef][Medline] [Order article via Infotrieve]
3. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson’s disease. Science. 2003; 302: 819–822.
4. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 2001; 292: 1552–1555.
5. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, Kurosawa M, Nekooki M, Nukina N. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med. 2004; 10: 148–154.[CrossRef][Medline] [Order article via Infotrieve]
6. Heling A, Zimmermann R, Kostin S, Maeno Y, Hein S, Devaux B, Bauer E, Klovekorn WP, Schlepper M, Schaper W, Schaper J. Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ Res. 2000; 86: 846–853.
7. Kostin S, Pool L, Elsasser A, Hein S, Drexler HC, Arnon E, Hayakawa Y, Zimmermann R, Bauer E, Klovekorn WP, Schaper J. Myocytes die by multiple mechanisms in failing human hearts. Circ Res. 2003; 92: 715–724.
8. Sanbe A, Osinska H, Saffitz JE, Glabe CG, Kayed R, Maloyan A, Robbins J. Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A. 2004; 101: 10132–10136.
9. Weekes J, Morrison K, Mullen A, Wait R, Barton P, Dunn MJ. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics. 2003; 3: 208–216.[CrossRef][Medline] [Order article via Infotrieve]
10. Vicart P, Caron A, Guicheney P, Li Z, Prevost MC, Faure A, Chateau D, Chapon F, Tome F, Dupret JM, Paulin D, Fardeau M. A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat Genet. 1998; 20: 92–95.[CrossRef][Medline] [Order article via Infotrieve]
11. Wang X, Osinska H, Klevitsky R, Gerdes AM, Nieman M, Lorenz J, Hewett T, Robbins J. Expression of R120G-alphaB-crystallin causes aberrant desmin and alphaB- crystallin aggregation and cardiomyopathy in mice. Circ Res. 2001; 89: 84–91.
12. Brady JP, Garland DL, Green DE, Tamm ER, Giblin FJ, Wawrousek EF. AlphaB-crystallin in lens development and muscle integrity: a gene knockout approach. Invest Ophthalmol Vis Sci. 2001; 42: 2924–2934.
13. Kumarapeli AR, Horak KM, Glasford JW, Li J, Chen Q, Liu J, Zheng H, Wang X. A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin. FASEB J. 10.1096/fj.05-3973fje. Published online September 27, 2005.
14. Dong X, Liu J, Zheng H, Glasford JW, Huang W, Chen QH, Harden NR, Li F, Gerdes AM, Wang X. In situ dynamically monitoring the proteolytic function of the ubiquitin-proteasome system in cultured cardiac myocytes. Am J Physiol Heart Circ Physiol. 2004; 287: H1417–H1425.
15. Verma R, Oania R, Graumann J, Deshaies RJ. Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin-proteasome system. Cell. 2004; 118: 99–110.[CrossRef][Medline] [Order article via Infotrieve]
16. Perng MD, Muchowski PJ, van Den IP, Wu GJ, Hutcheson AM, Clark JI, Quinlan RA. The cardiomyopathy and lens cataract mutation in alphaB-crystallin alters its protein structure, chaperone activity, and interaction with intermediate filaments in vitro. J Biol Chem. 1999; 274: 33235–33243.
17. Kumarapeli AR, Wang X. Genetic modification of the heart: chaperones and the cytoskeleton. J Mol Cell Cardiol. 2004; 37: 1097–1109.[Medline] [Order article via Infotrieve]
18. Sarikas A, Carrier L, Schenke C, Doll D, Flavigny J, Lindenberg KS, Eschenhagen T, Zolk O. Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc Res. 2005; 66: 33–44.
19. Wang X, Klevitsky R, Huang W, Glasford J, Li F, Robbins J. AlphaB-crystallin modulates protein aggregation of abnormal desmin. Circ Res. 2003; 93: 998–1005.
20. Fan GC, Chu G, Kranias EG. Hsp20 and its cardioprotection. Trends Cardiovasc Med. 2005; 15: 138–141.[CrossRef][Medline] [Order article via Infotrieve]
21. Fan GC, Chu G, Mitton B, Song Q, Yuan Q, Kranias EG. Small heat-shock protein Hsp20 phosphorylation inhibits beta-agonist-induced cardiac apoptosis. Circ Res. 2004; 94: 1474–1482.
22. Sanchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature. 2003; 421: 373–379.[CrossRef][Medline] [Order article via Infotrieve]
23. Li HH, Kedar V, Zhang C, McDonough H, Arya R, Wang DZ, Patterson C. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest. 2004; 114: 1058–1071.[CrossRef][Medline] [Order article via Infotrieve]
24. Lindsten K, Menendez-Benito V, Masucci MG, Dantuma NP. A transgenic mouse model of the ubiquitin/proteasome system. Nat Biotechnol. 2003; 21: 897–902.[CrossRef][Medline] [Order article via Infotrieve]
25. Luker GD, Pica CM, Song J, Luker KE, Piwnica-Worms D. Imaging 26S proteasome activity and inhibition in living mice. Nat Med. 2003; 9: 969–973.[CrossRef][Medline] [Order article via Infotrieve]
26. Elsasser S, Finley D. Delivery of ubiquitinated substrates to protein-unfolding machines. Nat Cell Biol. 2005; 7: 742–749.[CrossRef][Medline] [Order article via Infotrieve]
27. Meiners S, Heyken D, Weller A, Ludwig A, Stangl K, Kloetzel PM, Kruger E. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes. J Biol Chem. 2003; 278: 21517–21525.
28. Lim HW, Molkentin JD. Calcineurin and human heart failure. Nat Med. 1999; 5: 246–247.[CrossRef][Medline] [Order article via Infotrieve]
29. Foo RS, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest. 2005; 115: 565–571.[CrossRef][Medline] [Order article via Infotrieve]
30. Ghislain M, Udvardy A, Mann C. S. cerevisiae 26S protease mutants arrest cell division in G2/metaphase. Nature. 1993; 366: 358–362.[CrossRef][Medline] [Order article via Infotrieve]
31. Kedar V, McDonough H, Arya R, Li HH, Rockman HA, Patterson C. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc Natl Acad Sci U S A. 2004; 101: 18135–18140.
32. Gomes AV, Zong C, Edmondson RD, Berhane BT, Wang GW, Le S, Young G, Zhang J, Vondriska TM, Whitelegge JP, Jones RC, Joshua IG, Thyparambil S, Pantaleon D, Qiao J, Loo J, Ping P. The murine cardiac 26S proteasome: an organelle awaiting exploration. Ann N Y Acad Sci. 2005; 1047: 197–207.[CrossRef][Medline] [Order article via Infotrieve]
33. Okada K, Minamino T, Tsukamoto Y, Liao Y, Tsukamoto O, Takashima S, Hirata A, Fujita M, Nagamachi Y, Nakatani T, Yutani C, Ozawa K, Ogawa S, Tomoike H, Hori M, Kitakaze M. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation. 2004; 110: 705–712.
34. Marston SB, Redwood CS. Modulation of thin filament activation by breakdown or isoform switching of thin filament proteins: physiological and pathological implications. Circ Res. 2003; 93: 1170–1178.
35. Tanaka Y, Guhde G, Suter A, Eskelinen EL, Hartmann D, Lullmann-Rauch R, Janssen PM, Blanz J, von Figura K, Saftig P. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature. 2000; 406: 902–906.[CrossRef][Medline] [Order article via Infotrieve]
Related Article:
Circ. Res. 2005 97: 964-966.
This article has been cited by other articles:
 |
|
 |
|
  H. Su and X. Wang The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective Cardiovasc Res, September 16, 2009; (2009) cvp287v2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Tsukamoto, T. Minamino, and M. Kitakaze Functional alterations of cardiac proteasomes under physiological and pathological conditions Cardiovasc Res, September 4, 2009; (2009) cvp282v2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Carrier, S. Schlossarek, M. S. Willis, and T. Eschenhagen Ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy Cardiovasc Res, August 10, 2009; (2009) cvp247v2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Luo, J. Wong, and B. Wong Protein degradation systems in viral myocarditis leading to dilated cardiomyopathy Cardiovasc Res, August 6, 2009; (2009) cvp225v2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Willis, J. C. Schisler, A. L. Portbury, and C. Patterson Build it up-Tear it down: protein quality control in the cardiac sarcomere Cardiovasc Res, February 15, 2009; 81(3): 439 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Rothermel and J. A. Hill Autophagy in Load-Induced Heart Disease Circ. Res., December 5, 2008; 103(12): 1363 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R.K. Kumarapeli, H. Su, W. Huang, M. Tang, H. Zheng, K. M. Horak, M. Li, and X. Wang {alpha}B-Crystallin Suppresses Pressure Overload Cardiac Hypertrophy Circ. Res., December 5, 2008; 103(12): 1473 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Liu, H. Zheng, M. Tang, Y.-C. Ryu, and X. Wang A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2541 - H2550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Birks, N. Latif, K. Enesa, T. Folkvang, L. A. Luong, P. Sarathchandra, M. Khan, H. Ovaa, C. M. Terracciano, P. J.R. Barton, et al. Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy Cardiovasc Res, August 1, 2008; 79(3): 472 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Tannous, H. Zhu, J. L. Johnstone, J. M. Shelton, N. S. Rajasekaran, I. J. Benjamin, L. Nguyen, R. D. Gerard, B. Levine, B. A. Rothermel, et al. Autophagy is an adaptive response in desmin-related cardiomyopathy PNAS, July 15, 2008; 105(28): 9745 - 9750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Tannous, H. Zhu, A. Nemchenko, J. M. Berry, J. L. Johnstone, J. M. Shelton, F. J. Miller Jr, B. A. Rothermel, and J. A. Hill Intracellular Protein Aggregation Is a Proximal Trigger of Cardiomyocyte Autophagy Circulation, June 17, 2008; 117(24): 3070 - 3078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Simon, J.-M. Fontaine, J. L. Martin, X. Sun, A. D. Hoppe, M. J. Welsh, R. Benndorf, and P. Vicart Myopathy-associated {alpha}B-crystallin Mutants: ABNORMAL PHOSPHORYLATION, INTRACELLULAR LOCATION, AND INTERACTIONS WITH OTHER SMALL HEAT SHOCK PROTEINS J. Biol. Chem., November 23, 2007; 282(47): 34276 - 34287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Lowe, R. A. Kley, P. F.M. van der Ven, M. Himmel, A. Huebner, M. Vorgerd, and D. O. Furst The pathomechanism of filaminopathy: altered biochemical properties explain the cellular phenotype of a protein aggregation myopathy Hum. Mol. Genet., June 1, 2007; 16(11): 1351 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sanbe, J. Yamauchi, Y. Miyamoto, Y. Fujiwara, M. Murabe, and A. Tanoue Interruption of CryAB-Amyloid Oligomer Formation by HSP22 J. Biol. Chem., January 5, 2007; 282(1): 555 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang and J. Robbins Heart Failure and Protein Quality Control Circ. Res., December 8, 2006; 99(12): 1315 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Gomes, C. Zong, R. D. Edmondson, X. Li, E. Stefani, J. Zhang, R. C. Jones, S. Thyparambil, G.-W. Wang, X. Qiao, et al. Mapping the Murine Cardiac 26S Proteasome Complexes Circ. Res., August 18, 2006; 99(4): 362 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zong, A. V. Gomes, O. Drews, X. Li, G. W. Young, B. Berhane, X. Qiao, S. W. French, F. Bardag-Gorce, and P. Ping Regulation of Murine Cardiac 20S Proteasomes: Role of Associating Partners Circ. Res., August 18, 2006; 99(4): 372 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Powell The ubiquitin-proteasome system in cardiac physiology and pathology Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H1 - H19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Zolk, C. Schenke, and A. Sarikas The ubiquitin-proteasome system: Focus on the heart Cardiovasc Res, June 1, 2006; 70(3): 410 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Lindsten, V. Menendez-Benito, M. G. Masucci, N. P. Dantuma, A. R. K. Kumarapeli, K. M. Horak, H. Zheng, and X. Wang GFP reporter mouse models of UPS proteolytic function FASEB J, May 1, 2006; 20(7): 1027 - 1028. [Full Text] [PDF]
|
|
|
|
|
|
P. Razeghi and H. Taegtmeyer Cardiac Remodeling: UPS Lost in Transit Circ. Res., November 11, 2005; 97(10): 964 - 966. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||